{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:23:45Z","timestamp":1794914625523,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-amyloid monoclonal antibodies are entering clinical practice for early symptomatic Alzheimer\u2019s disease (AD), but European real-world data on feasibility, safety, and biomarker monitoring remain limited. We report the first year of implementation of lecanemab and donanemab in an Italian tertiary memory center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective observational real-world cohort study at the Center for Alzheimer\u2019s and Related Diseases of IRCCS Ospedale San Raffaele (Milan, Italy). Twenty-nine treatment courses were administered in patients with early symptomatic AD (lecanemab,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; donanemab,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) under European Medicines Agency\u2013aligned safety monitoring and risk-mitigation protocols. Given the unbalanced treatment groups, results are descriptive and not intended for direct comparison between treatments. Safety surveillance included serial magnetic resonance imaging for amyloid-related imaging abnormalities (ARIA) and systematic recording of infusion-related reactions. Biological monitoring included amyloid positron emission tomography with Centiloid quantification and plasma biomarkers (phosphorylated tau 181 and 217, glial fibrillary acidic protein, neurofilament light chain, and amyloid-\u03b2 42\/40 ratio) at baseline and follow-up. Baseline comparisons and longitudinal changes were assessed using appropriate parametric or nonparametric statistical methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ARIA were infrequent. In donanemab-treated patients, mildly symptomatic ARIA-E occurred in 10% (2\/20) and asymptomatic ARIA-H in 15% (3\/20). In lecanemab-treated patients, asymptomatic ARIA-H occurred in 11% (1\/9). Infusion-related reactions occurred in 21% (6\/29) of treatment courses and were manageable with standardized premedication. Among 11 patients with six-month follow-up, amyloid burden decreased significantly (mean change\u2009\u2212\u200952.4 Centiloids), and 75% of donanemab-treated patients (6\/8) and 0% of lecanemab-treated patients reached amyloid positron emission tomography negativity (&lt;\u200911CL). Plasma phosphorylated tau 181 and glial fibrillary acidic protein showed directional declines, consistent with expected biomarker trajectories under anti-amyloid therapy, while cognitive measures showed no significant change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a structured multidisciplinary framework, lecanemab and donanemab were feasibly implemented with a preliminary favorable early safety profile, substantial amyloid reduction, and measurable plasma biomarker changes in routine practice. This experience supports the feasibility of structured real-world pathways for deployment and monitoring of disease-modifying therapies in European memory clinics, within the limitations of a small cohort and short follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-026-02015-6","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:45:16Z","timestamp":1773971116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Federica","family":"Agosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo G.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Ghirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Rugarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Coraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Canu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Castelnovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sibilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Freri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vezzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Calloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Samanes Gajate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Panzacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"issue":"6","key":"2015_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"2015_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"2015_CR3","unstructured":"European Medicine Agency. Leqembi 2025 [updated 02\/10\/2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi."},{"key":"2015_CR4","unstructured":"European Medicine Agency. Kisunla 2025 [updated 28\/10\/2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla."},{"issue":"6","key":"2015_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center. J Prev Alzheimers Dis. 2024;11(6):1549\u201362.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"2015_CR6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D, et al. Lecanemab Treatment in a Specialty Memory Clinic. JAMA Neurol. 2025;82(7):655\u201365.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2015_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB, et al. Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):119.","journal-title":"Alzheimers Res Ther"},{"key":"2015_CR8","doi-asserted-by":"crossref","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Ghirelli A, Rugarli G, Pisano S et al. Anti-amyloid therapies and the transformation of Alzheimer\u2019s care pathways: early lessons from the frontline. Lancet Reg Health - Europe. 2026;64;101609.","DOI":"10.1016\/j.lanepe.2026.101609"},{"issue":"8","key":"2015_CR9","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2015_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"2015_CR11","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, et al. Donanemab: Appropriate use recommendations. J Prev Alzheimers Dis. 2025;12(5):100150.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"2015_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1\u2013e151.","journal-title":"Alzheimers Dement"},{"key":"2015_CR13","unstructured":"Combinostics. cNeuro\u00ae cPET and cDAT [Available from: https:\/\/www.combinostics.com\/."},{"issue":"4","key":"2015_CR14","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/alz.70062","volume":"21","author":"H Wang","year":"2025","unstructured":"Wang H, Serap Monkul Nery E, Ardayfio P, Khanna R, Otero Svaldi D, Gueorguieva I, et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimers Dement. 2025;21(4):e70062.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2015_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, et al. Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities. AJNR Am J Neuroradiol. 2025;46(1):24\u201332.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"2015_CR16","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1007\/s00415-024-12631-7","volume":"271","author":"G Cecchetti","year":"2024","unstructured":"Cecchetti G, Agosta F, Rugarli G, Spinelli EG, Ghirelli A, Zavarella M, et al. Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease: a real-world study. J Neurol. 2024;271(10):6739\u201349.","journal-title":"J Neurol"},{"issue":"8","key":"2015_CR17","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.tjpad.2025.100266","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang H, Nery ESM, Ardayfio P, Khanna R, Svaldi DO, Shcherbinin S, et al. The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J Prev Alzheimers Dis. 2025;12(8):100266.","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"2015_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ana.27233","volume":"98","author":"J Lagarde","year":"2025","unstructured":"Lagarde J, Maiti P, Schonhaut DR, Blazhenets G, Zhang J, Eloyan A, et al. Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer\u2019s Disease: Comparison of the LEADS and ADNI Cohorts. Ann Neurol. 2025;98(2):236\u201348.","journal-title":"Ann Neurol"},{"issue":"7","key":"2015_CR19","doi-asserted-by":"publisher","first-page":"e70491","DOI":"10.1002\/alz.70491","volume":"21","author":"I Gueorguieva","year":"2025","unstructured":"Gueorguieva I, Chow K, Chua L, Shcherbinin S, Zimmer JA, Evans CD, et al. Donanemab exposure-response in early symptomatic Alzheimer\u2019s disease. Alzheimers Dement. 2025;21(7):e70491.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"2015_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022;79(10):1015\u201324.","journal-title":"JAMA Neurol"},{"key":"2015_CR21","doi-asserted-by":"crossref","unstructured":"Benussi A, Agosta F, Alfano AR, Antico A, Bellelli G, Bonanni L, et al. Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease. Neurol Sci. 2025;46(12):6875\u201394.","DOI":"10.1007\/s10072-025-08576-y"},{"issue":"6","key":"2015_CR22","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00415-023-11642-0","volume":"270","author":"M Filippi","year":"2023","unstructured":"Filippi M, Cecchetti G, Cagnin A, Marra C, Nobili F, Parnetti L, et al. Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer\u2019s disease: an expert opinion and practical guideline. J Neurol. 2023;270(6):3159\u201370.","journal-title":"J Neurol"},{"issue":"1","key":"2015_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13195-025-01766-y","volume":"17","author":"KS Frederiksen","year":"2025","unstructured":"Frederiksen KS, Boada M, Dubois B, Engelborghs S, Frisoni GB, Georges J, et al. Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimers Res Ther. 2025;17(1):116.","journal-title":"Alzheimers Res Ther"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02015-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:31:17Z","timestamp":1781641877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02015-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to Italian regulations and institutional policy for observational studies conducted within routine care, formal ethics committee approval was not required. All participants provided written informed consent before treatment initiation, in accordance with the Ministerial Decree of February 11, 1997 and the Declaration of Helsinki and its subsequent amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"F. Agosta is Associate Editor of NeuroImage: Clinical and the European Journal of Neurology; has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon, Lilly, GE Healthcare, Eisai, and Bristol Myers Squibb; and receives or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council (ERC), the EU Joint Programme \u2013 Neurodegenerative Disease Research (JPND), and Foundation Research on Alzheimer Disease (France). G. Cecchetti has received speaker honoraria from Neopharmed Gentili and Eli Lilly. E.G. Spinelli received speaker honoraria from Eli Lilly. A. Ghirelli received speaker honoraria from Eli Lilly. G. Rugarli has nothing to disclose. S. Pisano has nothing to disclose. F. Coraglia has nothing to disclose. E. Canu has nothing to disclose. V. Castelnovo has nothing to disclose. E. Sibilla has nothing to disclose. A. Gilioli has nothing to disclose. C. Tripodi has nothing to disclose. F. Freri has nothing to disclose. A. Bianchi has nothing to disclose. P. Vezzulli has nothing to disclose. S. Calloni has nothing to disclose. A. Falini has nothing to disclose. AM Samanes Gajate has nothing to disclose. A. Panzacchi has nothing to disclose. G. Pepe has nothing to disclose. C. Ferri has nothing to disclose. A. Chiti reports consulting or advisory role for Blue Earth Diagnostics, Telix Pharmaceuticals, InnovaRadi Therapeutic, and General Electric Healthcare; and Speaker\u2019s Bureaus for Bracco Diagnostics, General Electric Healthcare, Novartis, Telix Pharmaceuticals, and United Imaging; he is Editor in Chief of The EANM Journal. M. Filippi is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Almirall, Biogen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Roche, Sanofi; speaking activities from Amgen, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Chiesi Italia SpA, Eisai, Eli Lilly, Fujirebio, Genzyme, Janssen, Merck, Neopharmed Gentili, Neuraxpharm, Novartis, Novo Nordisk, Roche, Sanofi, Takeda; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Eli Lilly, GE Healthcare Ltd, Merck, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}